Search

Displaying results 151 - 160 of 1723 in total
  1. Drug

    Cyanocobalamin

    go.drugbank.com/drugs/DB00115
    ApprovedInvestigationalNutraceutical

    This drug was initially approved by the FDA in 1942 [FDA label]. … The _cyano_ form, is the most widely used form in supplements and prescription drugs [A175255], [FDA label].

    Mixtures: DICLOVITH-B-FRT, FeRiva FA
  2. Drug

    Agkistrodon piscivorus antivenin

    go.drugbank.com/drugs/DB13894
    Approved

    It is intravenously (IV) administered to limit/prevent systemic toxicity [FDA label].

  3. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    It contains an amino acid sequence identical to the naturally occurring hormone consisting of 27 amino acids [FDA Label] that supports α-helical formation [A32275].

  4. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    It is intravenously administered to limit systemic toxicity [FDA label], [L2857], [L2858]. … CROFAB (crotalidae polyvalent immune fab (ovine))is a sheep-derived antivenin used for the management of adult and pediatric patients with North American crotalid envenomation [FDA label], which includes

  5. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

  6. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540].

  7. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure … As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment

  8. Drug

    Pemlimogene merolisbac

    go.drugbank.com/drugs/DB16286
    Investigational

    Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy...

    Synonyms: strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta protein (actan100), 5 tandem copies of a 21 amino acid fr
  9. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human throm...

  10. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA